Quest Diagnostics (DGX) Tops Q2 EPS by 210c
Tweet
Share
E-mail
Get Alerts DGX Hot Sheet
Price: $237.14 -0.94%
Revenue Growth %: +7.8%
Financial Fact:
Total operating costs and expenses: 1.56B
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: +7.8%
Financial Fact:
Total operating costs and expenses: 1.56B
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Quest Diagnostics (NYSE: DGX) reported Q2 EPS of $4.96, $2.10 better than the analyst estimate of $2.86. Revenue for the quarter came in at $2.55 billion versus the consensus estimate of $2.38 billion.
GUIDANCE:
Quest Diagnostics sees FY2021 EPS of $10.65-$11.35, versus the consensus of $11.13. Quest Diagnostics sees FY2021 revenue of $9.54-9.79 billion, versus the consensus of $9.45 billion.
For earnings history and earnings-related data on Quest Diagnostics (DGX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EU proposes to curb Airbnb and short-term rentals amid housing shortage
- UiPath Inc. (PATH) Reports In-Line Q2 EPS; offers guidance
- John Wiley & Sons, Inc. (WLYB) Misses Q1 EPS by 2c ; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
